Beta Drugs Ltd.
Beta Drugs Limited develops, manufactures, and sells anti-cancer bulk drugs and finished dosages in India. The company offers cosmeceutical and oncology products. It also manufactures active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI). The company exports its products. Beta Drugs Limited was founded in 1985 and is based in Panchkula, India.
Beta Drugs Ltd. (BETA) - Net Assets
Latest net assets as of : ₹- INR
Based on the latest financial reports, Beta Drugs Ltd. (BETA) has net assets worth ₹- INR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹-) and total liabilities (₹-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Beta Drugs Ltd. - Net Assets Trend (None–None)
This chart illustrates how Beta Drugs Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Beta Drugs Ltd. (None–None)
The table below shows the annual net assets of Beta Drugs Ltd. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Beta Drugs Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Beta Drugs Ltd. Competitors by Market Cap
The table below lists competitors of Beta Drugs Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Finch Therapeutics Group Inc
PINK:FNCH
|
$21.11 Million |
|
BRIDGETEC Corp
KQ:064480
|
$21.11 Million |
|
Molecure S.A.
WAR:MOC
|
$21.11 Million |
|
Gencurix Inc
KQ:229000
|
$21.11 Million |
|
Abico FS Co Ltd
TWO:8071
|
$21.09 Million |
|
Tridomain Performance Materials PT
JK:TDPM
|
$21.09 Million |
|
Success Prime Corp
TW:2496
|
$21.08 Million |
|
Royal Road Minerals Limited
PINK:RRDMF
|
$21.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Beta Drugs Ltd.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Beta Drugs Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Beta Drugs Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Beta Drugs Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Beta Drugs Ltd. (BETA) | ₹- | N/A | N/A | $21.10 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |